<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02874586</url>
  </required_header>
  <id_info>
    <org_study_id>AIH-2</org_study_id>
    <nct_id>NCT02874586</nct_id>
  </id_info>
  <brief_title>Plasma Exchange Combination of Immunosuppressive Regimens for Auto-immune Hepatitis</brief_title>
  <official_title>Plasma Exchange Combination of Immunosuppressive Regimens for the Remission of Auto-immune Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiaoli Fan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label,pilot study to evaluate the efficacy and safety of plasma exchange combination
      of immunosuppressive regimens, for the remission of autoimmune hepatitis (AIH).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of patients that achieve biochemical remission of AIH</measure>
    <time_frame>Month 6 after the treatment initiated</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alanine transaminase (ALT)</measure>
    <time_frame>Day 1, and Week 1, 2, 4, 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate transaminase(AST)</measure>
    <time_frame>Day 1, and Week 1, 2, 4, 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Globin(GLB)</measure>
    <time_frame>Day 1, and Week 1, 2, 4, 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin G(IgG)</measure>
    <time_frame>Day 1, and Week 1, 2, 4, 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total bilirubin(TB)</measure>
    <time_frame>Day 1, and Week 1, 2, 4, 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct bilirubin(DB)</measure>
    <time_frame>Day 1, and Week 1, 2, 4, 12, 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatitis, Autoimmune</condition>
  <arm_group>
    <arm_group_label>Plasma exchange combination of immunosuppressive regimens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasma exchange(once) ,with the following standard immunosuppressive regimens for the remission of auto-immune hepatitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Plasma exchange combination of immunosuppressive regimens</intervention_name>
    <arm_group_label>Plasma exchange combination of immunosuppressive regimens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with auto-immune hepatitis based on liver biopsy results, with the
             indications of immunosuppressive therapy;

          -  High levels of total bilirubin (TB) (≥10 X ULN);

          -  High levels of immunoglobulin G(IgG) (≥1.5 X ULN);

          -  Agreed to participate in the trial, and assigned informed consent;

        Exclusion Criteria:

          -  The presence of hepatitis A, B, C, D, or E virus infection;

               -  Patients with presence of liver cirrhosis or portal hypertension;

               -  Primary sclerosing cholangitis, non-alcoholic steatohepatitis, drug induced liver
                  disease or Wilson disease confirmed by liver biopsy;

               -  Pregnant and breeding women;

               -  Patients with severe anemia (hemoglobin &lt; 8 g/dL), leukopenia (WBC &lt; 2500/mm3),
                  or thrombocytopenia (platelet count &lt; 50,000/mm3);

               -  Severe disorders of other vital organs, such as severe heart failure, cancer;

               -  Parenteral administration of blood or blood products within 6 months before
                  screening;

               -  Recent treatment with drugs having known liver toxicity;

               -  Taken part in other clinic trials within 6 months before screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Yang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>West China Hospital,Chengdu, Sichuan, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoli Fan, MM</last_name>
    <phone>+862885422311</phone>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Yang, MD</last_name>
      <phone>+8618980601276</phone>
      <email>yangli_hx@scu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2016</study_first_posted>
  <last_update_submitted>December 8, 2016</last_update_submitted>
  <last_update_submitted_qc>December 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Xiaoli Fan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

